Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Multiple Myeloma Treatment Companies

Multiple myeloma is a type of cancer that affects plasma cells, a type of white blood cell. Companies specializing in pharmaceuticals develop and manufacture medications for the treatment of multiple myeloma. Companies involved in multiple myeloma treatment provide a range of products and services, including medications, therapies, and support solutions. 

Multiple Myeloma Treatment Companies

 


Latest Multiple Myeloma Treatment Companies Updates:


Pfizer Secured conditional approval in the EU for their BCMA-targeted immunotherapy Belantamab maftrumet (BLENFLEXA) for relapsed/refractory multiple myeloma (RRMM).Initiated Phase 3 clinical trials investigating BLENFLEXA in combination with other therapies for earlier treatment settings in multiple myeloma.


Bristol Myers Squibb (US) Reported positive Phase 2 data demonstrating the efficacy and safety of their BCMA-directed CAR-T cell therapy lisocabtagene marocileucel (Cellection) in heavily pretreated patients with RRMM.Received FDA Breakthrough Therapy designation for Cellection in combination with lenalidomide and dexamethasone for treating RRMM.


Janssen Pharmaceuticals (US) Announced promising initial data from their Phase 2 trial evaluating daratumumab monotherapy for the treatment of smoldering multiple myeloma.Partnered with academic institutions to investigate new treatment strategies involving CAR-T cell therapy and bispecific T-cell engagers for multiple myeloma.


AbbVie Inc. (US) Received FDA fast track designation for their investigational BCMA-targeted antibody-drug conjugate, eltanahtib, for treating RRMM.Collaborated with patient advocacy groups to expand access to clinical trials and support patients with multiple myeloma.


The Multiple Myeloma Research Foundation (MMRF) Launched a new research initiative focusing on identifying and targeting drug resistance mechanisms in multiple myeloma.Funded clinical trials investigating promising new therapies and personalized treatment approaches for multiple myeloma patients.


List of Multiple Myeloma Treatment Key companies in the market



  • Celgene Corporation

  • Janssen Biotech, Inc.

  • Bristol-Myers Squibb Company

  • Novartis AG

  • Millennium Pharmaceuticals

  • Amgen, Inc.

  • Genzyme Corporation

  • Juno Therapeutics

  • Johnson & Johnson

  • Hoffmann-La Roche Ltd.

  • GlaxoSmithKline plc

  • AbbVie Inc.

  • Novartis AG

  • Innate Pharma SA

  • Celldex Therapeutics, Inc.

  • Onyx Pharmaceuticals

  • Pfizer

  • Takeda Pharmaceuticals


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.